<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; IMS Health Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/ims-health-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(RX) IMS Health Reports Earnings In Line</title>
		<link>http://www.stockbloghub.com/2010/02/10/rx-ims-health-reports-earnings-in-line/27662</link>
		<comments>http://www.stockbloghub.com/2010/02/10/rx-ims-health-reports-earnings-in-line/27662#comments</comments>
		<pubDate>Thu, 11 Feb 2010 00:17:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[RX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27662</guid>
		<description><![CDATA[IMS Health (RX) reported fourth-quarter earnings per share (EPS) of 39 cents, in line with the Zacks Consensus Estimate. However, after adjusting for charges related to restructuring initiatives, asset impairment and others, EPS came in at 52 cents compared to 50 cents in the year-ago period. For the full year of 2009, IMS reported an EPS of $1.73 after adjustments compared to $1.70 in 2008. Revenues during the reported quarter came in at $599.2 million, an increase of 3% compared to the corresponding period last year. This is an improvement from the third quarter when curtailed spending by clients due to the economic downturn brought down revenues by 6%. For 2009, revenues came in at $2.18 billion, down 6% compared to $2.32 billion in 2008. IMS categorizes its revenue under ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/10/rx-ims-health-reports-earnings-in-line/27662/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Pharma &amp; Biotech Stock Review &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385</link>
		<comments>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385#comments</comments>
		<pubDate>Sat, 30 Jan 2010 00:08:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26385</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) IMS Health to be Acquired by Funds Managed by TPG Capital</title>
		<link>http://www.stockbloghub.com/2009/11/14/rx-ims-health-to-be-acquired-by-funds-managed-by-tpg-capital/20537</link>
		<comments>http://www.stockbloghub.com/2009/11/14/rx-ims-health-to-be-acquired-by-funds-managed-by-tpg-capital/20537#comments</comments>
		<pubDate>Sat, 14 Nov 2009 23:42:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[RX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20537</guid>
		<description><![CDATA[IMS Health (RX) recently agreed to its acquisition by investment funds managed by TPG Capital (TPG) and the Canada Pension Plan Investment Board (CPPIB) for a total value of $5.2 billion. The Board of Directors approved the decision based on the Transaction Committee recommendation, which was set up to review IMS’ strategic alternatives. Following the agreement, IMS shareholders will receive $22 cash for each share of IMS stock they own. The transaction is likely to be completed by the first quarter of 2010. The transaction will be financed by a combination of equity to be invested by TPG and CPPIB and debt financing to be provided by Goldman Sachs &#38; Co. Incorporatedluding its principal loan and mezzanine funds. Earlier, in October, IMS announced that it is exploring several strategic alternatives. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/rx-ims-health-to-be-acquired-by-funds-managed-by-tpg-capital/20537/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Big Pharma and Biotech &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146</link>
		<comments>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146#comments</comments>
		<pubDate>Mon, 09 Nov 2009 23:57:38 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as the products losing patent protection have. With most of the big pharma companies already facing patent challenges for their ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) IMS Health Earnings Ahead of Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2009/10/22/rx-ims-health-earnings-ahead-of-consensus-estimates/18548</link>
		<comments>http://www.stockbloghub.com/2009/10/22/rx-ims-health-earnings-ahead-of-consensus-estimates/18548#comments</comments>
		<pubDate>Thu, 22 Oct 2009 22:43:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[RX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18548</guid>
		<description><![CDATA[This morning, IMS Health (RX) reported third-quarter earnings per share of 40 cents, beating the Zacks Consensus Estimate by 4 cents. However, earnings declined 7% from the year-ago period. Revenues came in at $540.8 million. With clients reining in their spending due to the economic downturn, revenues declined 6%. Curtailed spending should continue affecting revenues. Operating income for the quarter was $100.8 million, down 21% from the year-ago period. The company did not undertake any share repurchasing activities during the quarter even though 9.5 million shares remain authorized and available for repurchase. Preliminary free cash flow was $155.2 million. The company exited the quarter with $301.7 million in cash and cash equivalents. Total debt declined to $1,344.9 million, compared to $1,404.2 million at the end of 2008. The company reported ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/22/rx-ims-health-earnings-ahead-of-consensus-estimates/18548/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

